NCT03247530View on ClinicalTrials.gov

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

477

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

September 12, 2018

Study Completion Date

September 12, 2018

Conditions
ADHD
Interventions
DRUG

Placebo

Placebo was administered once daily

DRUG

100mg SPN-812

100mg SPN-812 was administered once daily and compared to placebo

DRUG

200mg SPN-812

200mg SPN-812 was administered once daily and compared to placebo

Trial Locations (7)

14618

Finger Lakes Clinical Research, Rochester

33012

Indago Research & Health Center, Inc., Hialeah

36303

Harmonex Neuroscience Research, Dothan

77098

Houston Clinical Trials, Houston

77381

Family Psychiatry of the Woodlands, The Woodlands

83642

Advanced Clinical Research, Meridian

84058

Aspen Clinical Research, Orem

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT03247530 - Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD | Biotech Hunter | Biotech Hunter